- Reaction score
- 174
Kintor Pharmaceutical Phase 3 Trial Results for KX-826 and GT20029 | Hair Loss Cure 2020
Kintor Pharma (China)'s hair loss trials are for two androgen receptor (AR) targeting products: A degrader (GT20029) and an antagonist (KX-826) Pyrilutamide.
"However, compared with the placebo group, the total area hair count (TAHC) improvement in the KX-826 treated group had no statistical significance."
Another one bites the dust.
